Skip to main content
. Author manuscript; available in PMC: 2020 Oct 1.
Published in final edited form as: J Control Release. 2019 Sep 6;311-312:273–287. doi: 10.1016/j.jconrel.2019.09.006

Table 2:

Stratification of mice into five treatment groups and evaluation of responses to therapy, toxicity, and recurrence. CR: complete response meaning no evidence of the tumor mass. PR: partial response meaning a decrease in tumor volume (≥25%). NR: no response meaning no significant decrease in tumor mass. Recurrence: increase in tumor mass after a complete or partial response. * Drug-related observable toxicity during treatment: More than 10% weight loss in a week or more than 20% weight loss over any time period; diarrhea, bulky ascites, distended abdomen, or lethargy.

Group Treatment Mice/group CR PR NR Treatment-Related Toxicity* Recurrence
G1 Vehicle control 5 0 0 5 0 N/A
G2 Cisplatin+ Paclitaxel 5 + 15 (mg/kg) 5 0 0 5 0 N/A
G3 Irinotecan 40 (mg/kg) 5 1 3 1 0 3
G4 Irinotecan 80 (mg/kg) 5 3 2 0 3 2
G5 ASC-shCE2:nLuc + Irinotecan 40 (mg/kg) 5 4 1 0 0 1